{"product_id":"prognostic-factors-in-patients-with-breast-cancer-liver-metastases-undergoing-liver-resection-a-patients-guide","title":"Prognostic Factors in Patients with Breast Cancer Liver Metastases Undergoing Liver Resection: A Patient's Guide","description":"\u003cp\u003eBreast cancer that spreads to the liver (breast cancer liver metastases, or BCLM) is a serious situation, and whether to remove these liver tumors surgically has been debated for many years. This large meta-analysis, combining 56 studies and 2,782 patients who underwent liver resection, found that surgery can improve long-term survival for carefully selected patients. The strongest predictors of better outcomes were having no lymph node involvement at the time of breast cancer surgery, having a single liver metastasis rather than multiple, waiting more than 24 months between the breast cancer diagnosis and the appearance of liver disease, and achieving a complete surgical removal of the liver tumor (an R0 resection).\u003c\/p\u003e\n\n\u003ch1\u003ePrognostic Factors in Patients with Breast Cancer Liver Metastases Undergoing Liver Resection: A Patient's Guide\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#methods\"\u003eHow the Research Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: What the Studies Showed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations of This Research\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Next Steps\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn a meta-analysis of 56 studies and 2,782 patients, liver resection for breast cancer liver metastases was linked to improved long-term survival in carefully selected patients.\u003c\/li\u003e\n\u003cli\u003eBetter outcomes were seen with no axillary lymph node involvement, a single liver metastasis, more than 24 months between diagnoses, and complete R0 resection.\u003c\/li\u003e\n\u003cli\u003ePositive axillary lymph nodes at breast surgery raised the risk of death by 74%, with consistent results across studies.\u003c\/li\u003e\n\u003cli\u003eSix comparative studies found no statistically significant survival difference between liver resection plus systemic therapy versus systemic therapy alone.\u003c\/li\u003e\n\u003cli\u003eThe ideal surgical candidate has a single liver lesion, no extrahepatic disease, a longer disease-free interval, and can undergo complete tumor removal with clear margins.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\n\u003cp\u003eBreast cancer is often initially a localized disease, but it can spread throughout the body. The liver is the third most common site for breast cancer to metastasize, behind the lymph nodes and bones. When breast cancer spreads to the liver, survival without treatment is typically less than 8 months. For many years, the primary treatment for breast cancer liver metastases (BCLM) has been chemotherapy and, more recently, targeted immunotherapy.\u003c\/p\u003e\n\n\u003cp\u003eIn contrast, liver metastases from other cancers, such as colorectal cancer, are routinely removed surgically as part of standard care. The reason breast cancer liver metastases are different is that breast cancer cells tend to travel through the bloodstream more widely, so by the time liver metastases appear, there is often microscopic disease elsewhere. For colorectal cancer, the liver is often the first stop for cancer cells through the portal circulation, making liver resection a more straightforward proposition.\u003c\/p\u003e\n\n\u003cp\u003eBecause of this difference, the role of liver surgery in BCLM remains controversial. Previous studies have reported 5-year survival rates after liver resection ranging from as low as 9% to as high as 78% — a huge variation that reflects very different criteria used to select patients for surgery across various medical centers.\u003c\/p\u003e\n\n\u003cp\u003eThis study was designed to bring clarity to this debate. The authors performed a systematic review and meta-analysis of all available evidence on factors that predict survival after surgical removal of breast cancer liver metastases. By pooling data from thousands of patients, they aimed to identify which patients are most likely to benefit from liver resection and which are not.\u003c\/p\u003e\n\n\u003ch2 id=\"methods\"\u003eHow the Research Was Conducted\u003c\/h2\u003e\n\n\u003cp\u003eThe researchers followed strict international guidelines for systematic reviews, including the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) and AMSTAR (Assessing the Methodological Quality of Systematic Reviews) standards. The protocol was registered in advance in the PROSPERO database (registration number CRD42020212007) to ensure transparency and reproducibility.\u003c\/p\u003e\n\n\u003ch3\u003eSearch Strategy\u003c\/h3\u003e\n\u003cp\u003eAn electronic search of PubMed\/MEDLINE and the Cochrane Library was performed, with the last search date on 27 August 2020. The search used a combination of terms including \"breast,\" \"non-colorectal,\" \"hepatic,\" \"liver,\" \"metastasis,\" \"metastases,\" \"surgery,\" \"resection,\" and \"hepatectomy.\" The references of selected articles were also manually screened to ensure no relevant studies were missed.\u003c\/p\u003e\n\n\u003ch3\u003eStudy Selection\u003c\/h3\u003e\n\u003cp\u003eTwo independent reviewers screened titles and abstracts of all retrieved records. Studies were included if they met all of these criteria:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eOriginal articles about surgical treatment of breast cancer liver metastases\u003c\/li\u003e\n  \u003cli\u003eAt least 10 patients who had undergone liver resection\u003c\/li\u003e\n  \u003cli\u003ePublished in English\u003c\/li\u003e\n  \u003cli\u003eIncluded survival data for the resected patients\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eExcluded were reviews, editorials, comments, protocols, case reports (fewer than 10 patients), and articles focused only on local treatments like radiofrequency ablation or chemoembolization.\u003c\/p\u003e\n\n\u003cp\u003eA total of 2,623 studies were identified. After title and abstract screening, 2,441 records were excluded. Full-text screening was performed on 182 articles, and 56 publications met the final inclusion criteria. Of these, 32 provided enough data for the quantitative meta-analysis. Potential overlap of patients between studies from the same hospital was carefully handled by selecting only one study per group according to pre-defined priority rules.\u003c\/p\u003e\n\n\u003ch3\u003eData Extraction and Quality Assessment\u003c\/h3\u003e\n\u003cp\u003eTwo reviewers independently extracted information on study characteristics, patient demographics, disease features, surgical characteristics, and survival outcomes. Data included median age at liver resection, presence of synchronous liver metastases or extrahepatic disease, type of liver resection (major or minor), postoperative mortality and morbidity, median follow-up, overall survival (OS), and disease-free survival (DFS).\u003c\/p\u003e\n\n\u003cp\u003eQuality of the included studies was assessed using the Newcastle–Ottawa Scale (NOS), a standard tool for evaluating the quality of non-randomized studies.\u003c\/p\u003e\n\n\u003ch3\u003eDefinitions of Prognostic Factors\u003c\/h3\u003e\n\u003cp\u003eTo ensure consistent interpretation, the authors defined key factors as follows:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAxillary nodes:\u003c\/strong\u003e lymph nodes retrieved at breast surgery\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMultiple liver metastases:\u003c\/strong\u003e more than one liver lesion\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSize of liver metastasis:\u003c\/strong\u003e diameter greater than 3.0 cm\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSynchronicity:\u003c\/strong\u003e liver diagnosis within 1 year of treatment of the primary breast tumor\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAge at liver diagnosis:\u003c\/strong\u003e age under or over 50 years\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eShort\/long interval:\u003c\/strong\u003e less than or more than 24 months between breast and liver diagnosis\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eExtrahepatic disease:\u003c\/strong\u003e presence or absence of metastases outside the liver at the time of BCLM surgery\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eStatistical Analysis\u003c\/h3\u003e\n\u003cp\u003eThe meta-analysis used a random-effects model to calculate pooled hazard ratios (HRs) for 5-year overall survival. Hazard ratios express the relative risk of death at any time point — an HR above 1 means a factor is associated with worse survival, while an HR below 1 means a factor is protective. Statistical heterogeneity between studies was measured using the I² index, and publication bias was assessed using funnel plots, Egger's test, and Macaskill's test. A p-value less than 0.05 was considered statistically significant.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: What the Studies Showed\u003c\/h2\u003e\n\n\u003ch3\u003eQualitative Results (Systematic Review)\u003c\/h3\u003e\n\u003cp\u003eAll 56 included studies had a retrospective design, and only six had a control group of non-resected patients. The patients were predominantly female (as expected for breast cancer), with median ages at BCLM diagnosis ranging from 42 to 60 years.\u003c\/p\u003e\n\n\u003cp\u003eA total of 2,782 patients underwent liver resection for BCLM over a 38-year period (1980–2018). Among the studies:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e12 studies (21.4%) excluded patients with synchronous liver metastases\u003c\/li\u003e\n  \u003cli\u003e13 studies (23.2%) included patients with extrahepatic disease at the time of liver diagnosis\u003c\/li\u003e\n  \u003cli\u003e60% of studies reported a median follow-up of 38.2 months after liver resection (range 12–81 months)\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe median overall survival was 52 months (range 25–134.5 months) in 80% of studies. The cumulative 3-year overall survival was 62.5% (range 35.7–78%), and the 5-year overall survival was 42.7% (range 9.1–78%).\u003c\/p\u003e\n\n\u003cp\u003eDisease-free survival (DFS) — how long patients lived without the cancer returning — was reported in 28 out of 56 studies (50%). The median DFS after liver resection was 25.5 months. The cumulative 3-year DFS was 29.9% (range 8–46%), and the 5-year DFS was 21% (range 8–41.1%).\u003c\/p\u003e\n\n\u003ch3\u003eMeta-Analysis of Prognostic Factors\u003c\/h3\u003e\n\u003cp\u003eThirty-five studies provided data on factors that influenced survival after liver resection and were included in the quantitative analysis. The results were divided into factors related to the primary breast tumor and factors related to the liver metastases themselves.\u003c\/p\u003e\n\n\u003ch4\u003ePrimary Tumor Factors\u003c\/h4\u003e\n\u003cp\u003e\u003cstrong\u003eAxillary lymph node involvement\u003c\/strong\u003e at the time of breast cancer surgery was strongly associated with worse survival. The pooled hazard ratio was 1.74 (95% confidence interval 1.25–2.41, I² = 0%). This means that patients with positive axillary lymph nodes had a 74% higher risk of death during the follow-up period compared with patients without lymph node involvement. The I² of 0% indicates no significant statistical heterogeneity — this finding was very consistent across studies.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHormone receptor status\u003c\/strong\u003e of the primary tumor showed a hazard ratio of 0.90 (95% CI 0.58–1.41, I² = 66%), which was not statistically significant. This means that as a whole, receptor status did not clearly predict survival across all studies, likely because of the diversity of receptor definitions and patient subgroups.\u003c\/p\u003e\n\n\u003ch4\u003eLiver Metastasis (BCLM) Factors\u003c\/h4\u003e\n\u003cp\u003eThe pooled hazard ratio for factors related to the BCLM pattern — including \u003cstrong\u003emultiple liver metastases, size of the metastases, and short interval between primary tumor and liver disease\u003c\/strong\u003e — was 1.32 (95% CI 1.17–1.48, I² = 71%). This indicates a 32% higher risk of death for patients with these adverse features.\u003c\/p\u003e\n\n\u003cp\u003eFor \u003cstrong\u003esurgical and pathological features\u003c\/strong\u003e — specifically, the presence of microscopic or macroscopic residual disease after resection (R1\/R2) and the presence of extrahepatic disease — the pooled HR was 1.51 (95% CI 1.15–1.98, I² = 76%). This means these factors increased the risk of death by 51%.\u003c\/p\u003e\n\n\u003cp\u003eThe relatively high I² values (71% and 76%) indicate substantial heterogeneity among studies, meaning that the individual results varied considerably. This is important to understand when interpreting the pooled numbers.\u003c\/p\u003e\n\n\u003ch4\u003eSurgery vs. Systemic Treatment\u003c\/h4\u003e\n\u003cp\u003eSix comparative studies directly compared liver resection plus systemic therapy to systemic therapy alone. These showed no statistically significant difference between the two approaches (HR 0.89, 95% CI 0.41–1.96, I² = 90%). This finding is important because it suggests that the overall benefit of adding surgery to standard treatment remains uncertain, and careful patient selection is critical.\u003c\/p\u003e\n\n\u003ch3\u003eUnderstanding the Statistical Results\u003c\/h3\u003e\n\u003cp\u003eIn plain language, a hazard ratio represents the chance of an event (death or recurrence) happening in one group compared to another over time. An HR of 1.74 for positive lymph nodes means that, at any given time during follow-up, a patient with positive lymph nodes is 1.74 times more likely to have died than a patient with negative nodes, assuming all other factors are similar. The 95% confidence interval (1.25–2.41) is the range of values in which we can be 95% confident the true effect lies. Since the entire interval is above 1, this result is statistically significant.\u003c\/p\u003e\n\n\u003cp\u003eThe I² value indicates the percentage of variation across studies that is due to real differences rather than random chance. An I² of 0% means the studies are very consistent with each other; higher I² values (such as 71% or 76%) signal that studies differ substantially, so the pooled result should be interpreted more cautiously.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\n\u003cp\u003eThis research provides practical guidance for doctors and patients facing the difficult decision of whether liver surgery is worthwhile for breast cancer that has spread to the liver. The authors' analysis highlights several factors that can help identify candidates most likely to achieve favorable long-term outcomes.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003ePositive axillary lymph nodes\u003c\/strong\u003e at the time of breast cancer surgery are an adverse prognostic factor. Patients who had lymphatic spread had lower survival after liver resection than patients without nodal spread. This makes biological sense: positive lymph nodes suggest a more aggressive primary tumor that may have already released microscopic cancer cells into the bloodstream, so removing the visible liver lesion alone may not be enough to achieve long-term control.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eHormone receptor status\u003c\/strong\u003e is nuanced. The study found that patients with ER-positive (estrogen receptor-positive) primary tumors generally had better survival after BCLM resection than ER-negative patients, and triple-negative status (ER-negative, PR-negative, HER2-negative) was identified as an independent poor prognostic factor in prior literature. Interestingly, the receptor status of the liver metastasis itself may differ from the primary tumor in about one-third of cases. In triple-negative cases, surgery may be beneficial because it physically removes a chemo-resistant liver lesion even though the overall disease is biologically aggressive.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eCharacteristics of the liver metastases\u003c\/strong\u003e matter. Patients resected for multiple liver metastases had a shorter median disease-free survival than patients with a single liver lesion. Several studies also found decreased overall and disease-free survival for tumors 30 mm or larger (p = 0.041) or 40 mm or larger. The authors caution that these morphological features may reflect selection bias, since studies tended to include patients with single, small lesions.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eThe timing of liver disease\u003c\/strong\u003e is an important clue. An interval shorter than 24 months between the diagnosis of breast cancer and the appearance of liver metastases was consistently an adverse prognostic factor. A longer interval suggests less aggressive disease biology and better chances of benefiting from surgery.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eComplete surgical removal\u003c\/strong\u003e is critical. The study confirmed that surgical radicality matters for long-term outcomes — not just avoiding macroscopic residual disease (an R2 resection), but also achieving negative microscopic margins (an R0 resection vs. R1). In other words, surgery should aim to completely remove all visible liver tumor with clear microscopic borders to give patients the best chance of long-term survival.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eExtrahepatic disease\u003c\/strong\u003e — the presence of cancer outside the liver — was also associated with worse outcomes in some studies, though the picture is mixed. Some centers include patients with well-controlled bone metastases, while others do not. The authors note that there is no standardized definition of \"oligometastatic\" disease, which adds to the difficulty of comparing studies. A strict surveillance approach after treatment of the primary tumor is necessary to detect metastatic disease early and to select patients with isolated liver lesions who could benefit from surgery.\u003c\/p\u003e\n\n\u003cp\u003eOverall, the research suggests that the \"ideal\" candidate for liver resection of breast cancer liver metastases would be a patient who had \u003cstrong\u003eno axillary lymph node involvement\u003c\/strong\u003e at breast surgery, currently has a \u003cstrong\u003esingle liver lesion\u003c\/strong\u003e, developed liver disease \u003cstrong\u003emore than 24 months after\u003c\/strong\u003e the original breast cancer diagnosis, and can undergo a \u003cstrong\u003ecomplete (R0) liver resection\u003c\/strong\u003e without evidence of extrahepatic disease.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations of This Research\u003c\/h2\u003e\n\n\u003cp\u003eEvery scientific study has limitations, and this meta-analysis is no exception. The authors openly acknowledge several important issues:\u003c\/p\u003e\n\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eRetrospective design:\u003c\/strong\u003e All included studies were retrospective, meaning they looked back at medical records. This type of design is more susceptible to bias than randomized controlled trials.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eSelection bias:\u003c\/strong\u003e Different studies used very different criteria to decide which patients were eligible for liver resection. This makes it difficult to compare results directly.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eMissing data:\u003c\/strong\u003e Some patients who had liver resections were included in larger reports on \"non-colorectal\" or \"non-neuroendocrine\" liver metastases, and their individual survival data could not be extracted for this analysis.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eLong time span:\u003c\/strong\u003e Studies spanned from 1980 to 2018. During those four decades, significant advances occurred in surgical techniques, imaging, pathological assessment, and systemic treatments (including HER2-targeted therapies). These changes could have influenced outcomes independently of the prognostic factors being studied.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eNeoadjuvant therapy not evaluated:\u003c\/strong\u003e The potential effect of chemotherapy or other treatments given before liver resection on survival could not be assessed because this information was not reported in the included studies.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eHeterogeneity:\u003c\/strong\u003e The high I² values (71% and 76%) for some analyses indicate substantial variability among studies. This means the pooled results should be interpreted with caution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eDespite these limitations, the authors note that this is, to their knowledge, the first meta-analysis to examine prognostic factors in both the primary breast cancer and the liver metastases for patients undergoing BCLM resection, and it evaluated long-term outcomes of more than 2,700 patients.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Next Steps\u003c\/h2\u003e\n\n\u003cp\u003eBased on these findings, what can patients and doctors take away? The decision to undergo liver resection for breast cancer liver metastases should be made on a case-by-case basis by a multidisciplinary team that includes breast surgeons, liver surgeons, medical oncologists, and radiologists. The following points are worth discussing with your medical team:\u003c\/p\u003e\n\n\u003col\u003e\n  \u003cli\u003e\n\u003cstrong\u003eKnow your primary tumor characteristics.\u003c\/strong\u003e Ask about your axillary lymph node status at the time of breast surgery and your tumor's hormone receptor and HER2 status. These factors can help predict whether liver surgery is likely to be beneficial.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eUnderstand your liver disease pattern.\u003c\/strong\u003e If you have a single liver metastasis, a longer disease-free interval since your breast cancer diagnosis, and no other sites of metastatic disease, you may be a better candidate for surgery. Multiple liver lesions, larger tumors, and a short interval are associated with worse outcomes.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eDiscuss the goal of surgery.\u003c\/strong\u003e The aim should be a complete resection with clear margins (R0 resection). If an R0 resection is unlikely, the benefit of surgery becomes less certain.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eConsider your overall health and treatment plan.\u003c\/strong\u003e Liver resection is a major operation. It should be considered as part of a comprehensive strategy that includes systemic therapies. The comparative studies in this meta-analysis did not show a clear advantage for surgery over systemic treatment alone, so surgery should not be viewed as a replacement for chemotherapy, targeted therapy, or hormonal therapy.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAsk about clinical trials.\u003c\/strong\u003e The authors emphasize that a randomized controlled trial (RCT) is urgently needed to validate these findings. Ask your doctor whether there are any ongoing trials evaluating surgical resection for breast cancer liver metastases.\u003c\/li\u003e\n\u003c\/ol\u003e\n\n\u003cp\u003eUltimately, this research provides hope that liver resection can offer long-term survival for a subset of patients with breast cancer liver metastases. But it also underscores the importance of careful patient selection based on both the biology of the original breast cancer and the characteristics of the liver disease itself.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat factors predict better survival after liver surgery for breast cancer that has spread to the liver?\u003c\/h3\u003e\n\u003cp\u003eBetter outcomes were linked to no lymph node involvement at the original breast cancer surgery, a single liver metastasis rather than multiple, a gap of more than 24 months between breast cancer diagnosis and liver disease, and complete surgical removal with clear margins. Each factor helped identify patients most likely to benefit from liver resection.\u003c\/p\u003e\n\u003ch3\u003eHow long do patients typically live after liver resection for breast cancer liver metastases?\u003c\/h3\u003e\n\u003cp\u003eAcross the studies reviewed, the median overall survival after liver resection was 52 months. The average 5-year survival rate was about 42.7%, but results varied widely, from 9% to 78%, depending on how carefully patients were selected for surgery and on their individual disease characteristics.\u003c\/p\u003e\n\u003ch3\u003eIs liver surgery better than chemotherapy or other systemic treatment alone?\u003c\/h3\u003e\n\u003cp\u003eSix comparative studies found no statistically significant difference in survival between liver resection plus systemic therapy and systemic therapy alone. This means the overall benefit of adding surgery remains uncertain, and careful patient selection is critical. Surgery should not replace chemotherapy, targeted therapy, or hormonal therapy.\u003c\/p\u003e\n\u003ch3\u003eDoes lymph node status at the time of my original breast cancer surgery affect my outcome after liver surgery?\u003c\/h3\u003e\n\u003cp\u003eYes. Having positive axillary lymph nodes at breast cancer surgery was strongly associated with worse survival after liver resection. In this analysis, patients with positive lymph nodes had a 74% higher risk of death during follow-up compared with patients whose lymph nodes were not involved.\u003c\/p\u003e\n\u003ch3\u003eDoes the time between my breast cancer diagnosis and the appearance of liver metastases matter?\u003c\/h3\u003e\n\u003cp\u003eYes. An interval shorter than 24 months between breast cancer diagnosis and liver metastases was consistently an adverse prognostic factor. A longer interval suggests less aggressive disease and a better chance of benefiting from liver surgery. This timing helps doctors identify which patients are most likely to have favorable long-term outcomes.\u003c\/p\u003e\n\u003ch3\u003eDoes having one or multiple liver metastases affect my chances after surgery?\u003c\/h3\u003e\n\u003cp\u003eYes. Patients who had surgery for multiple liver metastases had a shorter median disease-free survival than patients with a single liver lesion. Having more than one liver metastasis was associated with worse outcomes, so patients with a single isolated liver lesion may be better candidates for liver resection.\u003c\/p\u003e\n\u003ch3\u003eHow important is complete removal of the liver tumor during surgery?\u003c\/h3\u003e\n\u003cp\u003eComplete surgical removal with clear microscopic margins, called an R0 resection, is critical for long-term survival. Surgery that leaves microscopic or macroscopic disease (R1 or R2) carries a 51% higher risk of death. The goal should be complete removal, and if that is unlikely, the benefit of surgery becomes less certain.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Prognostic Factors in Patients with Breast Cancer Liver Metastases Undergoing Liver Resection\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Federica Galiandro, Salvatore Agnes, Giovanni Moschetta, Armando Orlandi, George Clarke, Emilio Bria, Gianluca Franceschini, Giorgio Treglia, and Francesco Giovinazzo\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eJournal:\u003c\/strong\u003e Cancers, 2022, Volume 14, Issue 7, Article 1691\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication date:\u003c\/strong\u003e Published 26 March 2022\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eDOI:\u003c\/strong\u003e 10.3390\/cancers14071691\u003c\/p\u003e\n\n\u003cp\u003eThis patient-friendly article is based on peer-reviewed research. It was written to help patients and their families understand the findings of the original study. Always consult your healthcare team for advice about your specific medical situation.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47458366390428,"sku":null,"price":0.0,"currency_code":"EUR","in_stock":true}],"url":"https:\/\/diagnosticdetectives.fi\/products\/prognostic-factors-in-patients-with-breast-cancer-liver-metastases-undergoing-liver-resection-a-patients-guide","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}